Palatin to host KOL webinar on PL9643 Phase 3 dry eye data on May 8, 2023

PALATIN TECHNOLOGIES INC

Webinar to review positive PL9643 Phase 3 MELODY-1 Lead-In population data for moderate to severe dry eye disease.
Final PL9643 Phase 3 MELODY-1 data expected in H2 2023; trial enrollment continuing.
Webinar moderated by CEO Carl Spana; featuring KOLs Dr. Stouch, Mr. Ousler, and CMO Dr. Raizman.
Company cites PL9643 positive effects on both signs and symptoms of dry eye disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.